Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
Leonardo Gomes da Fonseca, María Reig, Jordi Bruix
Clinics in Liver Disease (2020) Vol. 24, Iss. 4, pp. 719-737
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 113
Experience with regorafenib in the treatment of hepatocellular carcinoma
Alessandro Granito, A. Forgione, Sara Marinelli, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 109
USP2-Related Cellular Signaling and Consequent Pathophysiological Outcomes
Hiroshi Kitamura, Mayuko Hashimoto
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1209-1209
Open Access | Times Cited: 48
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
Ruyin Chen, Qiong Li, Shuaishuai Xu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma
Xinxiu Li, Hongmeng Su, Wenqing Tang, et al.
Investigational New Drugs (2024) Vol. 42, Iss. 2, pp. 185-195
Closed Access | Times Cited: 7
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development
Xin Li, Yaxi Wang, Xin Ye, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 37
Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
Sara Cherradi, Salomé Roux, Marie Dupuy, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Notch signaling maintains a progenitor-like subclass of hepatocellular carcinoma
Kay Seidel, Robert Piskol, Thi Thu Thao Nguyen, et al.
(2025)
Open Access
Notch signaling maintains a progenitor-like subclass of hepatocellular carcinoma
Kay Seidel, Robert Piskol, Thi Thu Thao Nguyen, et al.
(2025)
Open Access
Sorafenib-associated translation reprogramming in hepatocellular carcinoma cells
Laura Contreras, Alfonso Rodríguez‐Gil, Jordi Muntané, et al.
RNA Biology (2025)
Open Access
A molecularly imprinted electrochemical sensor based on highly selective and an ultra-trace assay of anti-cancer drug axitinib in its dosage form and biological samples
Ahmet Çetinkaya, S. Irem Kaya, Göksu Ozcelikay, et al.
Talanta (2021) Vol. 233, pp. 122569-122569
Closed Access | Times Cited: 32
Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells
Fuwen Yao, Yongqiang Zhan, Changzheng Li, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 21
Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 348-348
Open Access | Times Cited: 12
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
Alessandro Granito, Sara Marinelli, A. Forgione, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 477-492
Open Access | Times Cited: 26
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options
Margaretha A. Skowron, Mara Kotthoff, Felix Bremmer, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs
Catia Giovannini, Francesca Fornari, Fabio Piscaglia, et al.
Cells (2021) Vol. 10, Iss. 3, pp. 521-521
Open Access | Times Cited: 21
Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis
Dan Peng, Yongqing Cai, Geng Chen, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine
Mahmoud A. Younis, Hideyoshi Harashima
Pharmacogenomics and Personalized Medicine (2024) Vol. Volume 17, pp. 193-213
Open Access | Times Cited: 2
Development and validation of an immune‐related prognosis signature associated with hypoxia and ferroptosis in hepatocellular carcinoma
Chunbo Yang, Hanxin Feng, Chaoliu Dai
Cancer Medicine (2022) Vol. 11, Iss. 11, pp. 2329-2341
Open Access | Times Cited: 11
Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review
Roberto Cannella, Sara Lewis, Leonardo Gomes da Fonseca, et al.
American Journal of Roentgenology (2022) Vol. 219, Iss. 4, pp. 533-546
Closed Access | Times Cited: 11
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
International Journal of Cancer (2023) Vol. 154, Iss. 6, pp. 1043-1056
Closed Access | Times Cited: 6
<p>Huaier Suppresses the Hepatocellular Carcinoma Cell Cycle by Regulating Minichromosome Maintenance Proteins</p>
Yongjie Niu, Shan Liang, Han Gao, et al.
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 12015-12025
Open Access | Times Cited: 16
Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
Surabhi Pathak, Mohamad Bassam Sonbol
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1147-1158
Open Access | Times Cited: 12
Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review
Vanktesh Kumar, Navjot Kaur, Sanjeev Kumar Sahu, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 13, pp. 1464-1481
Closed Access | Times Cited: 8
A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study
Yanjun Cui, Ying Li, Li Xiao, et al.
Molecules (2022) Vol. 27, Iss. 4, pp. 1291-1291
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top